184 related articles for article (PubMed ID: 9071997)
1. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma.
Dei Tos AP; Doglioni C; Piccinin S; Maestro R; Mentzel T; Barbareschi M; Boiocchi M; Fletcher CD
J Pathol; 1997 Jan; 181(1):8-13. PubMed ID: 9071997
[TBL] [Abstract][Full Text] [Related]
2. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity.
Coindre JM; Hostein I; Maire G; Derré J; Guillou L; Leroux A; Ghnassia JP; Collin F; Pedeutour F; Aurias A
J Pathol; 2004 Jul; 203(3):822-30. PubMed ID: 15221942
[TBL] [Abstract][Full Text] [Related]
5. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
[TBL] [Abstract][Full Text] [Related]
6. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature.
Boltze C; Schneider-Stock R; Jäger V; Roessner A
Pathol Res Pract; 2001; 197(8):563-8. PubMed ID: 11518050
[TBL] [Abstract][Full Text] [Related]
7. Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma.
Dei Tos AP; Piccinin S; Doglioni C; Vukosavljevic T; Mentzel T; Boiocchi M; Fletcher CD
Am J Pathol; 1997 Dec; 151(6):1531-9. PubMed ID: 9403703
[TBL] [Abstract][Full Text] [Related]
8. Retroperitoneal liposarcoma with combined well-differentiated and myxoid malignant fibrous histiocytoma-like myxoid areas.
Hisaoka M; Morimitsu Y; Hashimoto H; Ishida T; Mukai H; Satoh H; Motoi T; Machinami R
Am J Surg Pathol; 1999 Dec; 23(12):1480-92. PubMed ID: 10584701
[TBL] [Abstract][Full Text] [Related]
9. Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection.
Butò S; Pierotti MA; Tamborini E; Della Torre G; Lavarino C; Rilke F; Pilotti S
Diagn Mol Pathol; 1999 Sep; 8(3):125-30. PubMed ID: 10565683
[TBL] [Abstract][Full Text] [Related]
10. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria.
Mariño-Enríquez A; Fletcher CD; Dal Cin P; Hornick JL
Am J Surg Pathol; 2010 Aug; 34(8):1122-31. PubMed ID: 20588177
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
12. Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22.
Pilotti S; Della Torre G; Lavarino C; Sozzi G; Minoletti F; Vergani B; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1998 Jun; 185(2):188-90. PubMed ID: 9713346
[TBL] [Abstract][Full Text] [Related]
13. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
Sánchez-Beato M; Piris MA; Martínez-Montero JC; García JF; Villuendas R; García FJ; Orradre JL; Martínez P
J Pathol; 1996 Sep; 180(1):58-64. PubMed ID: 8943816
[TBL] [Abstract][Full Text] [Related]
14. TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus.
Skomedal H; Kristensen GB; Nesland JM; Børresen-Dale AL; Tropé C; Holm R
J Pathol; 1999 Apr; 187(5):556-62. PubMed ID: 10398121
[TBL] [Abstract][Full Text] [Related]
15. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
16. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas.
Schneider-Stock R; Walter H; Radig K; Rys J; Bosse A; Kuhnen C; Hoang-Vu C; Roessner A
J Cancer Res Clin Oncol; 1998; 124(10):532-40. PubMed ID: 9829856
[TBL] [Abstract][Full Text] [Related]
17. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. Molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans.
Hisaoka M; Okamoto S; Morimitsu Y; Tsuji S; Hashimoto H
Virchows Arch; 1998 Oct; 433(4):323-9. PubMed ID: 9808434
[TBL] [Abstract][Full Text] [Related]
18. No correlation of c-myc overexpression and p53 mutations in liposarcomas.
Schneider-Stock R; Walter H; Rys J; Radig K; Hoang-Vu C; Roessner A
Virchows Arch; 1998 Oct; 433(4):315-21. PubMed ID: 9808433
[TBL] [Abstract][Full Text] [Related]
19. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma.
Coindre JM; Mariani O; Chibon F; Mairal A; De Saint Aubain Somerhausen N; Favre-Guillevin E; Bui NB; Stoeckle E; Hostein I; Aurias A
Mod Pathol; 2003 Mar; 16(3):256-62. PubMed ID: 12640106
[TBL] [Abstract][Full Text] [Related]
20. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
Pfister C; Larue H; Moore L; Lacombe L; Veilleux C; Tetu B; Meyer F; Fradet Y
Int J Cancer; 2000 Jan; 89(1):100-4. PubMed ID: 10719738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
